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A B S T R A C T
IL-23 is produced by antigen presenting cells and plays critical roles in immune response in rheumatoid
arthritis. In this study, we investigated whether the RhoA/Rho-kinase pathway is required to elevate
TLR2-mediated IL-23 production in synovial macrophages from patients with rheumatoid arthritis (RA),
and then examined the suppressive effect of cilostazol on these pathways. IL-23 production was elevated
by lipoteichoic acid (LTA), a TLR2 ligand, and this elevation was more prominent in RA macrophages than
in those from peripheral blood of normal control. LTA increased the activation of RhoA in association
with increased the nuclear translocation of NF-kB and its DNA-binding activity. Pretreatment of RA
macrophages with the pharmacological inhibitors exoenzyme C3 (RhoA), Y27632 (Rho-kinase) or
BAY11-7082 (NF-kB) inhibited IL-23 production by LTA. Inhibition of the RhoA/Rho-kinase pathway by
these drugs attenuated NF-kB activation. Cilostazol suppressed the TLR2-mediated activation of RhoA,
decreased NF-kB activity with down-regulated IL-23 production, and these effects were reversed by Rp-
cAMPS, as an inhibitor of cAMP-dependent protein kinase. The expression of IL-23, which colocalized
with CD68(+) cells in knee joint of CIA mice, was signiﬁcantly attenuated by cilostazol along with the
decreased severity of arthritis. Taken together, the RhoA/Rho-kinase pathway signals TLR2-stimulated
IL-23 production in synovial ﬂuid macrophages via activation of NF-kB. Thus it is summarized that
cilostazol suppresses TLR2-mediated IL-23 production by suppressing RhoA pathway via cAMP-
dependent protein kinase activation.
 2013 Elsevier Inc. All rights reserved.
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Rheumatoid arthritis (RA) is a common autoimmune and
chronic inﬂammatory joint disease characterized by increased
inﬁltration of macrophages, proliferation of synovial ﬁbroblast
with joint destruction [1]. When abundant monocytes/macro-
phages in the synovial ﬂuid of RA patients are activated, they
produce high levels of cytokines and chemokines, such as
interleukin-1b (IL-b), tumor necrosis factor a (TNFa), IL-6, and
MCP-1, which contribute to chronic inﬂammation and joint
destruction [2,3].Abbreviations: CIA, collagen induced arthritis; IL-23, interleukin-23; LTA, lipotei-
choic acid; RA, rheumatoid arthritis; TLR2, toll like receptor 2.
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http://dx.doi.org/10.1016/j.bcp.2013.08.017Toll-like receptors (TLRs) are conserved receptors that
recognize pathogen-associated molecular patterns, and play
important roles in innate and adaptive immunity [4]. TLR2 are
mainly expressed on cells, such as macrophages and dendritic
cells; and act as primary sensors by recognizing diverse ranges
of stimuli [5]. The lipoteichoic acid (LTA) and peptidoglycan are
recognized mainly by TLR-2 [6]. It has been reported that TLR2
stimulation causes the preferential induction of IL-8 and IL-23
p19 [7]. IL-23 is involved in autoimmune diseases like RA and
psoriasis, in which the cellular function of IL-23 is associated
with the self-reactive productions of IL-17, IL-6, and TNF-a, and
thus IL-23 plays a critical role in development of autoimmune
inﬂammation [8]. Furthermore, they reported that mice deﬁ-
cient in IL-23 (p19/) were relatively resistant to the
development of joint and bone inﬂammation in a collagen-
induced arthritis (CIA) model.
The Rho-GTPase family of monomeric RhoA, Rac1 and Cdc42
is known to cycle between the inactivated GDP-bound state and
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implicated in various cellular processes, such as the cell cycle,
cytoskeletal regulation, cellular growth and apoptosis [10,11].
Furthermore, it has been reported that RhoA is a key regulator of
transcription factors, NF-kB [12], and that inhibition of Rho-
kinase reduces the severity of synovial inﬂammation in rats with
CIA [13].
Although it has been demonstrated that IL-23 production plays
a crucial role in inﬂammatory reactions associated with rheuma-
toid arthritis [14], the signal pathway by which TLR2 induces IL-23
production in RA synovial macrophages has not been deﬁned. On
the other hand, cilostazol, a type-III phosphodiesterase inhibitor,
has been reported to have anti-inﬂammatory effects due to the
cAMP-dependent protein kinase activation-coupled suppression of
NF-kB gene transcription [15].
Therefore, in the present study, we undertook to investigate
the signal transduction pathways responsible for TLR2-mediated
IL-23 production in synovial ﬂuid macrophages from RA
patients: in particular, the present study highlighted implication
of the RhoA/ROCK signal pathway in the regulation of TLR2-
mediated IL-23 production in RA macrophages. We found that
increased IL-23 production by TLR2 involves the activation of
NF-kB via a RhoA/ROCK pathway. Further, cilostazol was found
to inhibit TLR2-mediated IL-23 production by suppressing RhoA
activity via the activation of cAMP-dependent protein kinase,
and to suppress the expression of IL-23 in the knee joints of CIA
mice.
2. Materials and methods
2.1. Reagents and antibodies
Lipoteichoic acid (LTA), BAY11-7082 and Y27632, were
obtained from Sigma (St. Louis, MO). Rp-cAMPS was purchased
from Alexis (San Diego, CA). Clostridium botulinum exoenzyme C3
transferase (exoenzyme C3) was from Upstate Biotechnology (Lake
Placid, NY. Anti-TLR2 antibody was from Abcam (Cambridge, MA).
NF-kB p65, IkBa, Histone H1and RhoA antibodies were from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA). TLR2 neutralizing
antibody was from eBioscience (San Diego, CA). IgG isotype
control antibody (R&D systems, Minneapolis, MN). Cilostazol
(OPC-13013), [6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-
dihydro-2-(1H)-quinolinone, >98.5% purity by HPLC, mean parti-
cle size, 14–28 (mean, 20) mm] was donated by Otsuka
Pharmaceutical Co. Ltd. (Tokushima, Japan), and was dissolved
in dimethyl sulfoxide to produce a 10 mM stock solution.
2.2. Cell preparations
Synovial ﬂuid samples were obtained from the knees of 20 RA
patients. All patients fulﬁlled the 1987 revised criteria of the
American College of Rheumatology at the time of therapeutic
arthrocentesis. Informed consent was obtained from all patients
and the study protocol was approved by the ethics committee of
Dong-A University Hospital (Busan, South Korea). Peripheral
blood was donated by ﬁve healthy volunteer donors. Mononu-
clear cells (MC) from the peripheral blood (PB) or synovial ﬂuid
(SF) were isolated by Ficoll Paque (Sigma) density gradient
centrifugation and cultured in RPMI 1640 containing 10% FBS for
1 h, when non-adherent cells were washed out, and
adherent SFMC were incubated in culture medium. Adherent
PBMC were allowed to differentiate into normal control
macrophages, as previously described by Liu et al. [16]. Cell
differentiation was determined by using monocyte/macrophage
markers by anti-CD14 antibody FACS. More than 90% of cells
were CD14-positive.2.3. RhoA activation assay
The levels of active GTP-bound RhoA were determined by pull-
down GTP-bound RhoA with GST-Rhotekin-RBD coupled to
glutathione agarose beads. Cells were stimulated with IGF-1 for
5 min, and lysed with lysis buffer (50 mM Tris, pH 7.5, 1% Nonidet
P-40, 150 mM NaCl, 5 mM MgCl2, 10% glycerol, 1 mg/ml leupeptin,
1 mg/ml aprotinin and 1 mM phenylmethylsulfonyl ﬂuoride).
Lysates were centrifuged, and supernatants were incubated with
beads coupled to GST- Rhotekin-RBD for 2 h at 4 8C. Beads were
then washed with lysis buffer and GTP-bound RhoA was eluted
with the sample buffer. Amounts of active RhoA were determined
by Western blot analysis.
2.4. Enzyme-linked immunosorbent assay
Levels of IL-23 in culture supernatants from synovial ﬂuid were
measured using an ELISA kit (R&D Systems, Minneapolis, MN)
according to the manufacturer’s protocol.
2.5. Immunocytochemistry
Cells were ﬁxed with 4% paraformaldehyde, permeabilized with
0.2% Triton X-100, incubated with anti-IL-23 (Abcam, Cambridge,
MA) for 1 h, and then with Cy3-conjugated secondary antibody for
30 min. Fluorescent images were obtained using a confocal
microscope (OLYMPUS FV-1000, Tokyo, Japan).
2.6. Western blotting assay
Proteins (30 mg) were resolved in a 10% SDS-polyacrylamide
electrophoresis gels and transferred to nitrocellulose membranes
(Amersham Biosciences, Inc., Piscataway, NJ). Blocked membranes
were then incubated with antibodies. Protein bands were
visualized with a chemiluminescent reagent from the Supersignal
West Dura Extended Duration Substrate Kit (Pierce Chemical,
Rockford, IL). Signals from bands were quantiﬁed using the UN-
SCAN-IT gel 5.1 software (Silk Scientiﬁc, Inc., Orem, UT). Results are
expressed as relative densities.
2.7. Small interfering RNA preparation and transfection
TLR2 siRNA oligonucleotides (GenBank accession number:
NM_003264.3) was synthesized by Bioneer (Daejeon, Korea).
siRNA negative control duplex was used as a control oligonucleo-
tide. Cells were transfected with TLR2 siRNA using Lipofectamine
2000 (Invitrogen).
2.8. NF-kB transcription factor assay
To quantify NF-kB transcription factor levels in nuclear
extracts, cell lysates were extracted using a nuclear extraction
kit (Chemicon International, Temecula, CA) according to manufac-
turer’s protocol. DNA binding activities of NF-kB p65 were
determined using a colorimetric NF-kB p65 transcription factor
assay kit (Rockland Immunochemicals, Gilbertsville, PA) according
to the manufacturer’s protocol.
2.9. Animals
Male DBA/1J mice were purchased from Japan SLC, Inc.
(Shizuoka, Japan). Mice were used for experiments when 8–12
weeks old. All experimental procedures were conducted in
accordance with the Animal Care Guidelines of the Animal
Experimental Committee of the College of Medicine, Pusan
National University.
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To produce the CIA model, 100 mg of bovine type II collagen
(Chondrex, Redmond, WA) dissolved in 0.1 M acetic acid was
emulsiﬁed with an equal volume of Freund’s complete adjuvant
(Sigma, St. Louis, MO). Mice were sensitized by an intradermal
injection at the tail base and a booster dose (with the CII and
Freund’s incomplete adjuvant) was administered in the same
manner 21 days later. Cilostazol (30 mg/kg/day) was administered
intraperitoneally beginning on day 22. Mice were euthanized on
day 38 after the initial injection, and knee joints were isolated.
Severities of arthritis in each individual limb were assessed
evaluating by erythema, swelling, and other changes, and the
clinical severity of arthritis was scored on a scale of 0–4, where
0 = normal; 1 = slight erythema or swelling; 2 = distinct erythem-
atous swelling; 3 = joint distortion; and 4 = ankylosis of the joint.
Histologic severity of arthritis was scored on a scale of 0–3, where
0 = normal; 1 = minimal synovial inﬂammation, with cartilage and
bone erosion limited to discrete foci; 2 = synovial inﬂammation
and moderate erosion, with normal joint architecture; and
3 = severe inﬂammation and severe erosion, with disrupted joint
architecture, as previously described by Williams et al. [17].
2.11. Immunoﬂuorescence
Dual immunoﬂuorescent staining was performed to identify
CD68 and IL-23 expressing cells using anti-CD68 and anti-IL-23
antibody. Serial sections (6-mm thick) were cut from a parafﬁn
block and non-speciﬁc antibody binding was blocked with CAS
Block (Zymed Laboratories, Inc., San Francisco, CA) for 10 min.
Sections were incubated for 1 h at room temperature with
antibodies, washed, incubated with secondary antibodies for
30 min at room temperature, and mounted using Vectashield
mounting medium (Vector Laboratories, Inc., Burlingame, CA).
Fluorescent images were obtained using a confocal microscope
(OLYMPUS FV-1000).Fig. 1. Activation of TLR2 induces the production of IL-23 in RA synovial macrophages
peripheral blood (PB) from healthy volunteers. Cells were incubated with LTA (5 mg/ml) 
macrophages were transfected with negative control siRNA or TLR2 siRNA, and then inc
production by anti-TLR2 antibody (Ab, 10 mg/ml) in RA macrophages. (E) Confocal micros
visualize cell nuclei). Results are expressed as the mean  SEM of 4–5 experiments (#P 2.12. Statistical analysis
Results are expressed as means  SEMs. Signiﬁcances of results
were analyzed by one-way analysis of variance (ANOVA) followed by
Tukey’s Multiple Comparison Test. The Student’s t-test was used to
determine the signiﬁcance of the difference between treated and
untreated groups. P values of less than 0.05 were considered
signiﬁcant.
3. Results
3.1. TLR2 induces the production of IL-23 in RA synovial macrophages
High constitutive expressions of TLRs, including TLR2, have
been reported in monocytes/macrophages immediately after cell
isolation procedures [18]. However, the signaling pathways
downstream of TLR2 activation in the pathogenesis of rheumatoid
arthritis are unclear. To examine whether the production of IL-23
in RA macrophages is mediated through TLR2 signal pathways, we
compared IL-23 levels after treating SF and PB macrophages from
healthy controls with LTA (a TLR2 ligand). IL-23 levels in RA and PB
macrophages when measured in conditioned media by ELISA, and
were found to be signiﬁcantly elevated 24–48 h after treatment
with LTA (5 mg/ml). Furthermore, stimulation with LTA (1–10 mg/
ml) for 48 h increased the production of IL-23 in a time- and
concentration-dependent manner. IL-23 production in SF macro-
phages from RA patients contained signiﬁcantly higher level than
macrophages from PB controls (Fig. 1A and B).
In addition, we conﬁrmed the involvement of TLR2 in the
increase in IL-23 production. RA macrophages transfected with
TLR2 siRNA showed a reduction of TLR2 protein levels to 15% of
the control level. In these TLR2-knockdown cells, LTA failed to
increase IL-23 production, which contrasted to its effect in
negative control cells (Fig. 1C). In addition, pretreatment with
anti-TLR2 antibody (10 mg/ml) inhibited LTA-induced IL-23
production (P < 0.01) (Fig. 1D). Confocal microscopic images. (A and B) The production of IL-23 by RA macrophages in synovial ﬂuid (SF) and
for various times and with various LTA concentrations (1–10 mg/ml) for 48 h. (C) RA
ubated with LTA (5 mg/ml) for 48 h. (D) Inhibition of LTA (5 mg/ml)-induced IL-23
copic images of IL-23 in RA macrophages treated with LTA for 48 h (DAPI was used to
< 0.05; ##P < 0.01; ###P < 0.001 vs. 1 h LTA or no treatment).
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IL-23 up-regulation (Fig. 1E). These results indicate that in RA
macrophages LTA signiﬁcantly enhanced IL-23 production via the
mediation of TLR2.
3.2. Activation of RhoA by TLR2
We sought to assess the involvement of the RhoA/Rho-kinase
pathway in TLR2-mediated IL-23 production in RA macrophages.
Cells were pretreated with exoenzyme C3 (an inhibitor of the
small GTP-binding protein Rho A) or Y27632 (an inhibitor of ROCK)
for 30 min before LTA stimulation. As shown in Fig. 2A, IL-23
production was signiﬁcantly inhibited by exoenzyme C3 (50%),
and by Y27632 (55%). These results indicate that the RhoA/Rho-
kinase signaling pathway is implicated in TLR2-mediated IL-23
production in RA macrophages. Likewise, pretreatment with
BAY11-7082, a NF-kB inhibitor, signiﬁcantly reduced LTA-induced
IL-23 production, suggesting the involvement of NF-kB activation
in TLR2-mediated IL-23 production (Fig. 2A).
To conﬁrm RhoA activation stimulated by TLR2, we measured
levels of GTP-bound active form of RhoA using pull-down assay
with GTS-Rhotekin. LTA strongly stimulated RhoA activity within
3–10 min, and increased the level of active GTP-bound RhoA
2.06  0.33 fold at 3 min (P < 0.01) (Fig. 2A). On the other hand,
pretreatment with anti-TLR2 antibody (10 mg/ml) decreased RhoA
activity (Fig. 2B). We further examined whether cilostazol couldFig. 2. TLR2 stimulation leads to activation of Rho A. (A) Determination of IL-23 levels 
BAY11-7082 (10 mM) for 30 min, and then incubated with LTA (5 mg/ml) for 48 h. (B) Tim
macrophages. RhoA-GTP was assayed by pull-down with Rhotekin RBD agarose. (C) Inh
10 mg/ml). After pretreatment with anti-TLR2 antibody (10 mg/ml) for 30 min, cells wer
activity. Cells were incubated with or without Rp-cAMPS (1 mM) for 30 min. After pretre
3 min. Results are expressed as the mean  SEM of 4–5 experiments (#P < 0.05; ##P < 0.
absence of Rp-cAMPS).suppress TLR-2 mediated RhoA activity. Indeed, LTA-induced up-
regulation of RhoA activity was signiﬁcantly attenuated by cilostazol
(1–30 mM) in a concentration-dependent manner. RhoA activity
suppressed by cilostazol was reversed by Rp-cAMPS (1 mM) (Fig. 2C),
implicating cAMP-dependent protein kinase activation in the action
of cilostazol.
3.3. Involvement of RhoA pathways in the activation of NF-kB
It has been reported that RhoA is a key regulator of transcription
factor NF-kB and cytokine expression [19]. To validate whether
RhoA pathways are involved in TLR2-mediated NF-kB activation,
RA macrophages were pretreated with Y27632 prior to LTA
application. Stimulation with LTA (5 mg/ml) signiﬁcantly de-
creased IkBa expression in the cytosol (0.54  0.02 fold,
P < 0.001) and increased the nuclear translocation of NF-kB
(1.95  0.06 fold, P < 0.01). Furthermore, pretreatment with
Y27632 (10 mM) signiﬁcantly inhibited LTA-stimulated IkBa degra-
dation and translocation of the nuclear NF-kB (Fig. 3A and B).
We examined the inhibitory effects of exoenzyme C3 (10 mM)
and Y27632 (10 mM) on the DNA binding activities of NF-kB p65
and compared these with that of BAY11-7082 (10 mM). LTA
increased NF-kB activity (2.67  0.27 fold, P < 0.001) was signiﬁ-
cantly inhibited by pretreatment with exoenzyme C3 and Y27632 or
BAY11-7082 (Fig. 3C), suggesting involvement of RhoA pathway in
the activation of NF-kB.by ELISA. Cells were pretreated with exoenzyme C3 (10 mM), Y27632 (10 mM), or
e-dependent enhancement of RhoA activity in the presence of LTA (5 mg/ml) in RA
ibition of the LTA-mediated activation of Rho A protein by anti-TLR2 antibody (Ab,
e further incubated with LTA (5 mg/ml). (D) Inhibitory effect of cilostazol on RhoA
atment with cilostazol (1–30 mM) for 4 h, cells were further incubated with LTA for
01; ###P < 0.001 vs. no treatment; **P < 0.01; ***P < 0.001 vs. LTA alone, yP < 0.05 vs.
Fig. 3. TLR2 induces NF-kB activation via RhoA signaling pathway. (A and B) LTA-induced suppression of cytosolic IkBa and augmentation of nuclear NF-kB expression were
reversed by Y27632 in RA macrophages. Cells were pretreated with Y27632 (10 mM) for 30 min and then LTA (5 mg/ml) was applied for 30 min. (C) An ELISA-based
transcription factor activation assay was performed using an oligonucleotide containing a NF-kB consensus binding site. Nuclear extracts from cells pretreated with
exoenzyme C3 (10 mM), Y27632 (10 mM), or BAY11-7082 (10 mM) were incubated for 30 min before LTA application. Results are expressed as the mean  SEM of 4–6
experiments (##P < 0.01; ##P < 0.001 vs. none; *P < 0.05; **P < 0.01; ***P < 0.001 vs. LTA alone).
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cilostazol
Whether cilostazol could inhibit TLR2-mediated RhoA activity-
linked NF-kB activation was assessed. In line with these results,
cilostazol (1–30 mM) signiﬁcantly increased IkBa expression in
cytosol that was decreased by LTA, and in turn decreased NF-kB
p65 translocation into the nucleus in a concentration-dependent
manner. Accordingly, NF-kB DNA binding activity was concentra-
tion-dependently decreased by cilostazol (Fig. 4C). These suppres-
sive effects were reversed by Rp-cAMPS (1 mM), indicating that
cilostazol strongly suppresses the TLR2-mediated up-regulation of
NF-kB activity by inhibiting the RhoA pathway.
3.5. Suppression of IL-23 production by cilostazol
To conﬁrm the suppressive effect of cilostazol on TLR2-
mediated IL-23 production, we measured changes in IL-23 levels
in response to LTA in RA macrophages under treatment with
cilostazol. LTA-stimulated release of IL-23 (291.3  20.92 pg/ml,
P < 0.001) into culture medium was concentration-dependently
suppressed by cilostazol (1–30 mM), and this suppression was
antagonized by Rp-cAMPS (1 mM) (Fig. 5A). These results were
conﬁrmed by immunoﬂuorescence confocal images, which showed
that the LTA-stimulated increase in cytosolic IL-23 expression was
markedly attenuated by cilostazol (10 mM), and that this attenuation
was recovered by Rp-cAMPS (1 mM) (Fig. 5B). These results show that
TLR2-mediated IL-23 production is suppressed by cilostazol in RA
macrophages.Fig. 4. Effect of cilostazol on NF-kB activity by TLR2. (A–C) Cells were incubated with or w
4 h. Thereafter, LTA (5 mg/ml) was added and incubated for more 30 min. Results are
treatment; *P < 0.05; **P < 0.01 vs. LTA alone; yP < 0.05; yyP < 0.01 vs. absence of Rp-cAM3.6. Increased expression of IL-23 and CD68(+) cells in the joints of CIA
mice
We adopted an immunoﬂuorescence approach to assess the
effect of cilostazol on IL-23 production in mice with CIA. Mice
received cilostazol (30 mg/kg/day, i.p) after the booster injection.
As shown in Fig. 6A, IL-23 immunoﬂuorescence staining revealed
colocalization with CD68(+) cells in the synovial tissues of vehicle-
treated CIA mice. Following treatment with cilostazol (30 mg/kg/
day), the increased IL-23(+) cells which were colocalized with
CD68(+) cells were markedly decreased (Fig. 6A).
In addition, the joints of CIA mice treated with cilostazol
showed macroscopically decreased clinical scores: typical struc-
tural changes such as synovial hyperplasia and bone destruction
accompanied by increased pannus formation and cartilage erosion.
Histological analysis also showed signiﬁcantly attenuated synovial
tissue inﬂammation and reduced inﬂammatory cell inﬁltration in
the mice treated with cilostazol (30 mg/kg/day) (Fig. 6B–D).
4. Discussion
In the present study, we assessed the signaling pathways
involved in TLR2-induced IL-23 production in synovial ﬂuid
macrophages obtained from RA patients. The major ﬁndings of
this study are that RhoA/ROCK-linked NF-kB transcriptional
activity is required to elevate TLR2-mediated IL-23 production
in synovial macrophages, and that cilostazol signiﬁcantly sup-
presses TLR2-mediated IL-23 production by suppressing RhoA/
ROCK pathways via cAMP-dependent protein kinase activation.ithout Rp-cAMPS (1 mM) for 30 min and then treated with cilostazol (1–30 mM) for
 expressed as the mean  SEM of 4–6 experiments (##P < 0.01; ###P < 0.001 vs. no
PS).
Fig. 5. Cilostazol prevents IL-23 production via cAMP-dependent protein kinase activation. (A) Inhibitory effect of cilostazol on the LTA-induced production of IL-23 and its
reversal by Rp-cAMPS in RA macrophages. Cells were incubated with or without Rp-cAMPS (1 mM) for 30 min. After pretreatment with cilostazol (1–30 mM) for 4 h, cells
were further incubated with LTA (5 mg/ml) for 48 h. (B) Confocal microscopic images showing that cilostazol (10 mM) attenuated the LTA-induced increased expression of IL-
23, and the reversal of this attenuation by Rp-cAMPS. Results are expressed as the mean  SEM of 4–5 experiments (###P < 0.001 vs. no treatment; ***P < 0.001 vs. LTA alone;
yP < 0.05 vs. absence of Rp-cAMPS). (C) Hypothetical model showing the role of RhoA/Rho kinase-activated NF-kB transcription factor in the LTA-stimulated TLR2-induced IL-23
production in synovial ﬂuid macrophages, and cilostazol suppresses TLR2-coupled RhoA/Rho kinase activity, leading to inhibition of IL-23 production. Arrows with dotted lines
represent decreased effect on target molecules.
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cAMP levels in a concentration-dependent manner in the
macrophages from RA patients [20].
TLRs are expressed on macrophages and dendritic cells, and
these cells recognize a diverse range of endogenous and exogenous
stimuli through TLRs [5]. Several reports have revealed that
synovial tissues of RA patients exhibit increased TLR2 expression
on macrophages and ﬁbroblasts in the synovial lining, and this
TLR2 augments the production of chemokines [21,22]. In line withFig. 6. Increased expression of IL-23 in conjunction with CD68(+) cells in the joints of CIA
Histological sections of knee joints from control and CIA mice treated with vehicle or cil
were awarded to the knee joints of CIA mice (Results are expressed as the mean  SEMthese reports, TLR2-deﬁcient mice were reported to have
signiﬁcantly less severity of the arthritis [23].
IL-23 is produced by antigen presenting cells such as
macrophages [19], and plays a critical role for development of
autoimmune inﬂammation [3,24]. Mice deﬁcient in IL-23 (p19/
) was reported relatively resistant to the development of joint
and bone inﬂammation in the murine CIA model [8]. However,
the signal pathways responsible for IL-23 production by synovial
macrophages in response to TLR2 remain unclear. In the present mice. (A) Double immunoﬂuorescence staining for IL-23 (red) and CD68 (green). (B)
ostazol at 30 mg/kg/day. (C and D) Clinical and histological severity arthritis scores
 of 5–7 experiments (#P < 0.05; ## P < 0.01 vs. vehicle (Veh)-treated CIA mice).
S.Y. Park et al. / Biochemical Pharmacology 86 (2013) 1320–13271326study, the fact that LTA-stimulated TLR2 induced increased
production of IL-23 in RA SF macrophages was conﬁrmed using
anti-TLR2 antibody and TLR2-knockdown macrophages, and the
prominent up-regulation of IL-23 in LTA-stimulated RA macro-
phages was identiﬁed by the immunoﬂuorescence study.
Some reports have shown that the activation of Rho GTPase
is linked to the signaling cascade leading to NF-kB activation,
and that this activation regulates various cellular responses
[25]. Furthermore, NF-kB has been suggested to play a role in
TLRs-induced IL-23 p19 promoter activity [26]. In the present
study, LTA stimulation signiﬁcantly increased the level of
active GTP-bound RhoA, and the pre-application of anti-TLR2
antibody signiﬁcantly suppressed LTA-stimulated RhoA activity,
indicating that the action of LTA-stimulated RhoA activation was
mediated via TLR2 stimulation. Furthermore, our observations
that IL-23 production was signiﬁcantly inhibited by exoenzyme
C3 (an inhibitor of the small GTP-binding protein Rho A) and
by Y27632 (an inhibitor of ROCK) strongly indicate that
the RhoA/ROCK signaling pathway is implicated in TLR2-
mediated IL-23 production in RA macrophages. RhoA has been
reported a key regulator of transcription factors, such as NF-kB
[12], and blocking of Rho-kinase has been demonstrated to
reduce the severity of synovial inﬂammation in rats with CIA
[13]. In line with these reports, the LTA-induced down-
regulation of IkBa expression and the increased intranuclear
translocation of NF-kB were inhibited by pretreatment with
Y27632. Furthermore, the increased DNA binding activities of
NF-kB p65 by LTA were inhibited by pretreatment with
exoenzyme C3, Y27632 as was suppressed by BAY11-7082,
which suggests the involvement of RhoA in the activation of NF-
kB. This notion is supported by the ﬁndings of Liu et al. [16],
who found that TLR2 enhanced the expressions of IL-23 p19 via
the NF-kB pathways.
Previously, Park et al. [20] have revealed that in synovial
macrophages from RA patients, cilostazol down-regulates lipo-
polysaccharide-stimulated PU.1-linked TLR4 expression via cAMP-
dependent protein kinase activation, and that reduced TLR4 levels
lead to decreased IkBa degradation and NF-kB p65 nuclear
translocation associated with inhibition of inﬂammatory cytokine
production in synovial macrophages from RA patients. In the
present study, we have focused on the role of RhoA/Rho kinase-
activated NF-kB transcription factor in the LTA-stimulated TLR2-
induced IL-23 production in synovial ﬂuid macrophages. Interest-
ingly, cilostazol suppressed TLR2-coupled RhoA/Rho kinase
activity through cAMP-dependent protein kinase activation,
consequently inhibited IL-23 production (Fig. 5C).
It has been reported that LTA triggers signaling transduction
through TLR2 and that it activates p42/p44 MAPK and p38 MAPK in
myelo-monocytic cells [26], and these MAPKs mediate TLR
signaling pathways [28]. This raises the question as to whether
cilostazol inﬂuences the increased phosphorylations of ERK and
JNK after LTA challenge. Future studies are needed to determine
whether cilostazol regulates MAPKs, thereby mediating the signal
pathway: TLR2-mediated IL-23 production.
Based on these in vitro experiments using SF macrophages, we
sought to determine whether cilostazol ameliorates joint synovial
inﬂammation in a murine CIA model. Many reports have
emphasized inﬁltration of monocytes/macrophages in joint
inﬂammation associated with locally produced cytokines
[29,30]. In the present study, immunoﬂuorescent double staining
showed IL-23-expression co-localized with CD68-positive (a
marker of macrophage) cells in the knee joint synovium in CIA
mice, and that this expression was prominently attenuated by
cilostazol. In addition, cilostazol protected joints from synovial
tissue inﬂammation in CIA mice, according to histological and
clinical scores.Taken together, this study highlights the important role of
RhoA/ROCK pathway in the mediation of TLR2-stimulated IL-23
production via NF-kB activation in SF macrophages. Furthermore,
cilostazol was found to attenuate TLR2-mediated IL-23 production
by suppressing the RhoA/ROCK pathway via mediation of cAMP-
dependent protein kinase in synovial macrophages from RA
patients.
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